Get the Stockscreener App
0.4424
3.74%
-0.0172
After Hours:
.44
-0.0024
-0.54%
Immutep Limited Adr stock is traded at $0.4424, with a volume of 741.35K.
It is down -3.74% in the last 24 hours and up +22.89% over the past month.
Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.
See More
Previous Close:
$0.4596
Open:
$0.45
24h Volume:
741.35K
Relative Volume:
0.06
Market Cap:
$65.20M
Revenue:
-
Net Income/Loss:
$-54.17M
P/E Ratio:
-1.196
EPS:
-0.3699
Net Cash Flow:
$-39.34M
1W Performance:
-7.37%
1M Performance:
+22.89%
6M Performance:
-73.19%
1Y Performance:
-78.21%
1-Day Range:
$0.4379
$0.4522
1-Week Range:
$0.427
$0.485
52-Week Range:
$0.2928
$3.5299
Immutep Limited Adr Stock (IMMP) Company Profile
Compare IMMP vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMMP
Immutep Limited Adr
|
0.4424 | 67.73M | 0 | -54.17M | -39.34M | -0.3699 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Immutep Limited Adr Stock (IMMP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-26 | Downgrade | Citizens | Mkt Outperform → Mkt Perform |
| Mar-13-26 | Downgrade | Maxim Group | Buy → Hold |
| Mar-13-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-17-26 | Initiated | Citizens | Mkt Outperform |
| May-17-24 | Initiated | CapitalOne | Overweight |
| Aug-03-23 | Initiated | Robert W. Baird | Outperform |
| Aug-03-21 | Initiated | Ladenburg Thalmann | Buy |
| Jul-16-21 | Resumed | Maxim Group | Buy |
| Sep-28-18 | Initiated | B. Riley FBR | Buy |
| Feb-15-18 | Reiterated | Maxim Group | Buy |
View All
Immutep Limited Adr Stock (IMMP) Latest News
Rosen Law Firm Encourages Immutep Ltd. Investors to Inquire About Securities Class Action InvestigationIMMP - ChartMill
IMMP Investor News: If You Have Suffered Losses in Immutep Ltd. (NASDAQ: IMMP), You Are Encouraged to Contact The Rosen Law Firm About Your Rights - GlobeNewswire Inc.
IMMP Stock Price, Quote & Chart | IMMUTEP LTD-SP ADR (NASDAQ:IMMP) - ChartMill
IMMP Forecast, Price Target & Analyst Ratings | IMMUTEP LTD-SP ADR (NASDAQ:IMMP) - ChartMill
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Immutep Ltd. Investors to Inquire About Securities Class Action InvestigationIMMP - TMX Newsfile
ROSEN, A LEADING LAW FIRM, Encourages Immutep Ltd. Investors to Inquire About Securities Class Action InvestigationIMMP - TMX Newsfile
ROSEN, LEADING INVESTOR COUNSEL, Encourages Immutep Ltd. Investors to Inquire About Securities Class Action InvestigationIMMP - TMX Newsfile
Immutep Announces Abstract Accepted for Presentation at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting - Sahm
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immutep LimitedIMMP - ChartMill
Immutep LTD ADR (IMMP) News, Articles, Events & Latest Updates - Stocktwits
IMMP Investor Alert: Immutep Ltd. Securities Fraud InvestigationInvestors With Losses May Seek to Lead the Class Action After Company Allegedly Failed To Disclose Material Risks Related To Trial Viability : Levi & Korsinsky - Sahm
Nasdaq Surges 200 Points; Morgan Stanley Posts Upbeat Earnings - Sahm
Dow Gains 100 Points; Bank of America Earnings Top Views - Sahm
US Market Preview | IMMP Surges 200%; Trump on Iran War: 'Close to Over'; Tesla AI5 Chip Tapped Out; ASML Falls 3% After Weak Q2 Outlook - Sahm
U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.15% - Investing.com
These stocks are moving in today's session - ChartMill
Which stocks are most active on Wednesday? - ChartMill
Here are the top movers in Wednesday's session. - ChartMill
These stocks are moving in today's pre-market session - ChartMill
Immutep Receives FDA Orphan Drug Designation for Eftilagimod Alfa in Soft Tissue Sarcoma - ChartMill
Working capital per share of Immutep Ltd Sponsored ADR – FWB:YP1A - TradingView — Track All Markets
IMMP Investor News: If You Have Suffered Losses in Immutep - GlobeNewswire
ROSEN, A NATIONALLY RECOGNIZED INVESTOR RIGHTS LAW FIRM, Encourages Immutep Ltd. Investors to Inquire About Securities Class Action InvestigationIMMP - TMX Newsfile
POM IMPORTANT DEADLINE: ROSEN, LEADING TRIAL ATTORNEYS, Encourages PomDoctor Ltd. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 7 Deadline in Securities Class Action - GlobeNewswire Inc.
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Immutep Ltd. Investors to Inquire About Securities Class Action InvestigationIMMP - TMX Newsfile
IMMP Investors Have Opportunity to Join Immutep Limited Fraud Investigation with the Schall Law Firm - Business Wire
Immutep (NASDAQ: IMMP) reports positive Phase I progress for LAG-3 agonist IMP761 - Stock Titan
On Wednesday, there are stocks with unusual volume. Let's take a look. - ChartMill
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Immutep Limited (IMMP) And Encourages Investors to Reach Out - accessnewswire.com
Immutep Limited Adr Stock (IMMP) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.77%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):